Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06897475 · ClinicalTrials.gov registry record · Phase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

A Phase 2 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 2
Development phase
240
Enrollment target
20
Study locations

NCT06897475 is a Phase 2 study of Type 2 Diabetes that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 240 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06897475, a Phase 2 study of Type 2 Diabetes, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Placebo
  • DRUG LY3457263

Study Locations (20)

Texas

  • Juno Research - Houston
  • Southern Endocrinology Associates - Mesquite
  • Texas Diabetes & Endocrinology, P.A. - Round Rock
  • Consano Clinical Research, LLC - Shavano Park
  • Texas Valley Clinical Research - Weslaco

Florida

  • Renstar Medical Research - Ocala
  • Oviedo Medical Research - Oviedo

Georgia

  • Balanced Life Health Care Solutions/SKYCRNG - Lawrenceville
  • Rophe Adult and Pediatric Medicine/SKYCRNG - Union City

New York

  • Richmond University Medical Center - Staten Island
  • Southgate Medical Group - West Seneca

North Carolina

  • Lucas Research, Inc. - Morehead City
  • Shelby Clinical Research - Shelby

Arizona

  • Helios Clinical Research - Phoenix - Phoenix

California

  • Wolverine Clinical Trials - Santa Ana

Idaho

  • Elite Clinical Trials - Rexburg

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2025-03-28
Est. Completion 2027-01
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06897475

The ClinicalTrials.gov registry entry for NCT06897475 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (78% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06897475 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Texas, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06897475 about?

NCT06897475 is a clinical study titled "A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide". The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

What is the current status of trial NCT06897475?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-03-28. Estimated completion is 2027-01.

What conditions does trial NCT06897475 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT06897475?

The interventions under investigation include: Placebo (DRUG), LY3457263 (DRUG).

Who is sponsoring clinical trial NCT06897475?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06897475 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.